Faculty Strategic Plan

7/31/2019 Faculty Strategic Plan

1/90

)20152010(

1


2/90


3/90

231995

1994/1995

.

)2(

.

2004/2005

.

-2004

CIQAP

.

3


4/90

-" "

CIQAP

.

-.

-

.( )

-.

-

.

-

.

-)

( ) (

-.

-.

-.

-

.

-.

-.

:

4


5/90

.

:

:

.

.

.

. ,

, , ,

,

,

.

:

5


6/90

1-

:

1-.

2-.

3-.

2-

.

3-

/

51/33%

50/32.5%

16/10%

31/20%

7/4.5%

4-

/

17/40%

6/14.5%

5/12%6


7/90

4/9.5%

3/7%

6/14.5%

1/2.5%

5-

.

6-205

19/10/2009.

:

1-

.

2-5.

7


8/90

SWOT Analysis

.

:

1-.

2-.

3-

/

18/34.5%

14/27%

4/7.5%

9/17.5%

7/13.5%

4-

8


9/90

/

17/40%

6/14.5%

5/12%

4/9.5%

3/7%

6/14.5%

1/2.5%

5-.

6-.

7-205

19/10/2009.

9


10/90


11/90


12/90

:

.

Opportunities:

.

.

DAAD) Deutscher Akademischer Austausch

Dienst(Deutsche Forschungsgemeinschaft (DFG(

.

.

.

.

Threats:

.

.

.

.

.

.

.

:1-

2-

3-4-

12


13/90

5-6-7-

:

1-

2-

3-

4-

5-

-:1: -

%

%( )

90%

90%0.810.15

.

90

%

90%0.810.1

5.85

%85%0.720.1

3

.90%

95%0.860.16

20082012.

95%

95%0.90.17

( )

60

%

40%0.240.0

4

.65%

45%0.290.05

.

35%

60%0.210.04

.

30%

65%0.190.04

30%

50%0.150.03

3055%0.160.0

13


14/90

.%35.341.0

0

2: -

( )

0.15

40.6

.

0.1

5

30.45

.0.13

20.26

.

0.16

40.64

20082012.

0.17

50.85

( )

0.0

4

10.04

.

0.05

10.05

.

0.04

10.04

.

0.04

10.04

0.03

10.03

.

0.03

10.03

14


15/90

1.00

3.00

.

15


16/90

3: -

32-132-1220330

32-132-132-1

32-132-1

32-1220

32-132-1

220

:

:( - - )

:( - - )

:( - )

16


17/90

-:

1: -

%

%

( )

50%

85%0.430.1

.

60%

65%0.390.09

DAADDFG65%

70%0.450.11

.

65%

70%0.450.11

.

90%

90%0.810.19

( )

.

85

%

40%0.340.0

8

.

60%

50%0.300.07

.90%

40%0.360.08

.

55%

60%0.330.08

.

65%

50%0.330.08

4.191.00

17


18/90


19/90

19


20/90


21/90

5..6.

.7..

)T()S + T( ) ()W + T(( )

.1..2.

.3..

1..

.

.

.

.

( )

2,3


22/90


23/90


24/90

.


25/90

1.

.

2.

57357)3. (

3.P C R

.

4.:

)4.(

-

)5.(

.

5." "

.

6..

7.2010-

2011.


26/90

::::

:::

:

1..

2.

.

3.

.


27/90

4.

.

:

1..

2..

3.

)NARS. (

4.

.

5..

6.

7..


28/90

8..

9..

10..

11..

12..

13..

14.

.

15..

16.

.

1-

1-.

2-.

3-)NARS(


29/90

.

.4-

.5. -6-

.

2-

.

7-

8. -9-

.

3-

.

10-.

11. -12. -13. -14-

.

4-

15-16-

.

:

1-

:

1-.


30/90

2-.

3-

.

2-

.

3-

/

18/55%

3/9%

4/12%

2/6%

6/18%

4-211

11/1/2010.


31/90

:

1-

:

1-.

2-.

3-.

4-.

1-

.

2-

/

23/65.5%

5/14.5%2/5.5%

5/14.5%

3-21111/1/2010.


32/90

:

1-.

-.

1-

.

-.

2-

-:

.

.

.

4-

-


33/90


34/90

4

.

:

:

NARS

2025%25%

4045%35%

1723%17%

48%12%

510%6%

25%2%

25%3%

:


35/90

:

:

:

( )

::


36/90

:

.

:

.


37/90

:

1-

.

2-.

3-.

4-.

5-.

6-)218

31/5/2010(

7-.


38/90

:

1-

-

.

2-

-

.


39/90


40/90

)Objectives-:(

1-

2-

3-

.4-

.

5-

.

6-.7-

.

)policies-:(

1-.

2-

)Impact Factor(


41/90

3-

.

4-

.

5-

.

)Action plan-: (

1-

2-

.

3-

4-

.

5-

.

) -:Responsibilities-: (

1-/ .

2-

3-

.


42/90

4-( )

.

)Funding-:(

1-

2-CIQAP

3-

.

4-.

)Indicators-:(

1-.

2-.

3-

.

4-7.

5-.

6-

.

) -:Research items-:(

:

.

-

Under the theme of towards Safe and active of drugs


43/90

-

.

-

.

-

. / / /

-Production of new drug delivery systems treatment of

gnendisfunction related diseases and DNA vaccination as part of

cooperation in biotechnological field.

-Production of different dosage forms carrying drugs and

measuring the clinical efficacy of these forms on volunteers.

Comparing the newly produced dosage forms to what available in

market regarding bioavailability, clinical efficacy and toxicity.

-Quantitative estimation of natural compounds in pharmaceutical

products, stability and bioequivalence standards.

-Pharmaceutical effects of gum Arabic.

-Biological activities of medicinal plants pure compounds and its

extracts.

-Antimicrobial activities of pure compounds and medicinal plant

extracts

-Mutagenicity and carcinogenicity of medicinal herbal plant

extracts.


44/90

-Genetic manipulation of medicinal plants to enhance or modulate

the production of important active constituents.

-

.

.

.

-Applied and Environmental Microbiology: the department aims to

study the environmental risks and hazards on the surrounding

society in the Helwan area, which serves a large sector of the

population in Helwan governorate. Currently, a research project

deals with the microbiological analysis of drinking water.

-Biotechnology: this field of research utilizes bacteria like

Escherichia coli to produce valuable pharmaceutical products with

the least costs possible. The results of research studies can be

applied in industry to produce the desired product on the industrial

scale. The research work accomplished in a master's thesisoptimized the fermentation conditions that could be applied to

increase the production of liquid crystalline polymers.

-Clinical and pharmaceutical microbiology: the department is

interested in studying the rates of bacterial resistance to antibiotics

in the clinical settings (public hospital in Helwan and teaching

hospitals in other areas in Cairo). The outcome of research studies

will help determine the reason of treatment failure using antibiotics

(elucidate the mechanism of bacterial resistance to antibiotics). As

a result, clinicians will be able to decide what appropriate

treatment regimen to be used; thus reduce healthcare costs and

economic burden on the healthcare sector. Knowing the effective

treatment helps alleviate the pain and suffering of patients and


45/90


46/90

3-

.

4-.

5-.

6-

.

7-

.

8-.

9-

.

10-)

21315/2/2010.(

11-.

:

1-

-


47/90


48/90

2008/2012

:


49/90


50/90

:

1..2.

3.4.

:

1. .

2.

.

:

1.:

2.:

2008

2012


51/90


52/90

:

: :

:

1..

2.)( ----

.3.

.4..5..6.

7..

8..

: :

1..

2..3..4.5..6.

.7..8.Data Show.


53/90

:

1..2..

3. 4..5.

.

:

:

1..

2.

3..4..

5..

6..

7..

8..


54/90


55/90


56/90

.

+

2008-

2012

200,000

)

+(

2008-2008

150,000

2008-2010

500,000


57/90

+ +

2008-2010

400,000

+ +

2008-

2012

250,000

.

+ +2008-

2012150,000


58/90

.+ +

2008-2012

100,000

+

++

2008-2009

100,000

+

++

2008-2012

125,000

+

+

2008-2009

65,000


59/90

+

+

++

2008-2010

30,000

.

+

++

2008-2010

24,000

.

+

++

2008-2010

100,000

+

++

2008-2012

150,000


60/90

+

++

2008-2012

1,000,000

1,750,000

1,594,000

3,344,000


61/90

:

1.

2.3.

.4.

.5..6..7.

. 8..9.

.

:

1-


62/90

-

)

(

)

(-

2-

-

:

1-


63/90

-

2-

-

3-

-

.

.


64/90


65/90


66/90

2010 - 2015


67/90

-:

2 20

2010

1

2 20

2011

2

2 20

2011

3

2 20

2012

4

2 20

2012

5

2 20

2013

6

2 20

2013

7

2 20

2014

8

2 20

2014

9

2 20

2015

10

-


68/90

**


69/90

:

. )

. (

:2012

:1-

)SWOT(.

2-.

3-.


70/90


71/90

:

CIQA

P1/1

.

/11/1

1-2-

1-

2-

3-

1-2-3-

4-

2011-2011

75,000

25,000

50,00

0

1/1/2

1-2-3-

4-

2010

-

2011

5,000

5,000

1/2

.

1/2/1

.

1-13

CIQAP

1-

40%

1-2-3-

4-

2010

-20113,893,000

2,343,0

00

1,550,000

2-3

2011-2012

900,000

900,000


72/90

3-4

2012-

2013

1,200,000

1,200,0

00

1/2/2

.

1-2-3-

4-

1-

30%

1-2-3-4-5-6-7-CIQAP

2010

-

2011

150,000

150,00

0

1/2/3

.

1-2-3-4-

1-

10

1-2-

3-

4-

2011-

2013300,000

100,00

0

00,00

0

ouble

ourse

1/2/41-2-

1-

1-2-

2010-201275,000


73/90

.3-

4-

3-4-

35,00

0

40,00

0

1/2/51-2-

3-

4-

1-20%

2-

20%3-

1-2-

3-

2010-

2011

2,000

2,000

1/2/6

1-

2-

.

1-

15%

1-2-

3-

2011-

2011

50,000

10,00

0

40,00

0

1/2/7

1-2-

3-

1-

10%

1-2-

3-

4-

2011-

2011

20,000

20,00

0


74/90

1/2/8

1-2-

3-4-

1-

2-3-

4-

5-

6-

7-

8-

9-10-11-

1-2-

3-

4-

2010-

2011

50,000

14,50

0

35,500

1/3

)NARS(

1/3/1

)NARS(

1-2-3-4-5-

1-

2-3-

.

1-2-

3-

4-

2011-

2011

20,000


75/90

)

NARS(

.

5-6-

20,00

0

1/3/2

.

1-

2-3-

1-

CDC

1-

2-

3-4-

5-CDC

2011

-201220,000

20,00

0

ouble

ourse

1/3/3

)

(

1-

2-3-

4-

1-CDC

1-2-3-

4-

5-CDC

2010-

2011

10,000

10,00

0

1/3/4

1-

2-

1-

1-2-3-

2011-

2011

10,000


76/90

3-

4-

4-

10,00

0

IQAP

1/4

.

1/4/1

1-2-3-

4-

1-5%

2-

20%

1-2-3-

4-

2011-

2012

50,000

0,00

0

1/5

.

.

1/5/11-2-

3-4-

1-10%

2-3-

1-2-3-4-

5-

2011-

2012

50,000

40,00

0

0,00

0

1/5/2

1-2-

3-4-

1-

.2-

1-2-

3-

4-

2011-

2012

100,000

70,000

30,000


77/90

1/5/31-2-

3-4-

1-2-3-

1-2-

3-4-5-

2010-

2012

100,000

70,00

0

30,000

1/5/41-

1-101-2-

2012-2014

5,0001

5,0001

1/5/51-2-3-

1-1-2-3-4-

2010

-2011

5,000

5,000

1/6

)

Pharm.D(.

)Pharm.D(.

1/6/1

) Pharm.D(.

1-

2-

3-4-5-6-

1-2-

5%

1-2-

3-4-

2012-

2012

50,000

0,00

0


78/90

7-8-

.

1/6/2.

1-2-

2013-

2013

5,000

5,000

7,155,000

2,904,

500

2,585,

500

,665,0

00

:

.


79/90


80/90


81/90

:


82/90

CIQAP

3/10

.

.

3/10/1.

1-2-3-4-5-

1-

1-2-

3-

4-

2012-

2012

5,000

2,000

3,000

3/10/2

1-2-

1-

1-2-

2012-

5,000


83/90

2,000

3,000

3/10/3

1-2-3-4-

5-

1-.

1-2-

3-

4-

2010-

2011

10,000

10,000

3/10/41-2-3-4-5-

1-

2-3-4-

1-2-

3-

4-

2010-2011

10,000

10,000

3/11

.

3/11/1

.

1-2-

3-

4-

5-6-

1-

2-

1-2-

3-

4-

2010-

2013

30,000

10,00010,000

10,000


84/90

3/12

.

3/12/11-2-

3-4-

1-1-2-

3-4-

2012-2013

50,000

50,000

3/12/2

1-2-

3-4-

1-

10%

1-2-

3-4-

2013-

2014

10,000

10,000

3/12/31-2-

3-4-5-

1-

10%2-

3-

1-2-

3-4-

2013-

2014

5,000

5,000

3/12/41-2-

3-

1-

10%2-

1-2-

3-

2013-

2014

5,000


85/90

4-5-

3-

4-5,000

3/12/5

1-2-

3-

4-

1-

.

1-2-

3-4-

2013-

2013

3,000

3,000

3/12/61-2-3-

4-

1-1-2-

3-4-

2013-2013

5,000

5,000

3/13

..

3/13/11-2-3-

4-

1-

2-

1-2-

3-4-

2012-2013

3,000

3,000

3/13/2

.

1-2-

3-4-5-

1-

10%2-

3-

1-2-

3-4-

2013-

2014

5,000

5,000


86/90

3/13/31-2-

3-4-

5-

1-

10%2-

3-

1-2-

3-4-

2013-

2014

3,000

3,000

3/13/41-2-3-

4-

1-.

1-2-

3-4-

2013-2013

5,000

5,000

3/143/14/1

1-2-

3-4-

1-10%

1-2-

3-4-

2013-

2014

10,000

10,000

3/14/2

1-2-

3-4-

1-

10%

1-2-

3-4-

2013-

2014

5,000

5,000


87/90


88/90

4/15/2

1-2-3-

4-

5-

1-

1-2-3-

4-5-

2011-2012

6,000

5,0001,000

4/15/31-

2-3-

4-

5-

1-

.

1-2-

3-4-

2011-20113,000

3,000

4/16

.

4/16/1

1-

2-

3-

1-

20%

1-2-3-

4-5-

2011-2011

3,000

3,000

4/16/2

1-

2-

3-

1-

1-

2-3-

4-5-

2012-

2012

5,000

5,000


89/90

4/163/

1-

2-

3-

4-

1-

2-

3-

20%

1-2-3-

4-5-

2010-

2011

10,000

10,000

33,000

26,0002,0005,000

7,500,000

3,025,500

2,722,500

1,752,000


90/90

Documents

Faculty Strategic Plan